OncoMatch/Clinical Trials/NCT06341556
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Is NCT06341556 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Zanubrutinib for mantle cell lymphoma.
Treatment: Zanubrutinib — This study aims to evaluate whether maintenance therapy with Zanubrutinib monotherapy could improve the 2-year progression free survival (PFS) of patients with mantle cell lymphoma who had remission after first-line immunochemotherapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunochemotherapy with CD20 monoclonal antibody — first-line
Achieved complete response (CR) or partial response (PR) through first-line sufficient treatment (including immunochemotherapy with CD20 monoclonal antibody for at least 4 cycles). Frontline induction programs include but are not limited to: R-CHOP/R-DHAP, R-CHOP, BR, etc. Previous autologous hematopoietic stem cell transplantation is allowed
Lab requirements
Blood counts
Neutrophils ≥ 1.0 × 10^9/L, PLT ≥ 50 × 10^9/L, Hb ≥ 80g/L
Kidney function
serum Cr < 1.5 x ULN, creatinine clearance rate ≥ 50 mL/min (≥ 30 mL/min if renal dysfunction caused by tumor compression)
Liver function
bilirubin ≤ 1.5 x ULN, ALT and AST < 3 x ULN, serum albumin ≥ 30 g/L
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50% detected by echocardiography
Having sufficient organ function: a) Hematopoietic function: Neutrophils ≥ 1.0 × 10^9/L, PLT ≥ 50 × 10^9/L, Hb ≥ 80g/L; b) Liver function: bilirubin ≤ 1.5 times the upper limit of normal (ULN), ALT and AST<3 x ULN, serum albumin ≥ 30 g/L; c) Renal function: serum Cr<1.5 × ULN, creatinine clearance rate ≥ 50mL/min (calculated according to the standard Cockcroft Gault formula, if renal dysfunction is caused by tumor compression, creatinine clearance rate ≥ 30mL/min); d) Left ventricular ejection fraction (LVEF) ≥ 50% detected by echocardiography; e) Coagulation function (unless the subject is receiving anticoagulant therapy and the coagulation parameters (PT/INR and APTT) are within the expected range of anticoagulant therapy at the time of screening): International standardized ratio (INR) ≤ 1.5 x ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06341556 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received immunochemotherapy with CD20 monoclonal antibody.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages